Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up

Moderna (MRNA.O) and partner Merck & Co (MRK.N) said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.